Crestline Management, LP

Est. AUM

$46.27B

13F long equity, this entity only

Positions

Period

Mar 2026 (Q1)

SEC EDGAR

Mar 2026 (Q1)

#	Issuer	Class	Value	Shares	% Portfolio	Discretion
1	DENALI THERAPEUTICS INC	COM	$42.45B	2210732	91.74%	DFND
2	SANA BIOTECHNOLOGY INC	COM	$2.18B	755736	4.70%	DFND
3	8X8 INC NEW	COM	$1.64B	990850	3.56%	DFND

Values in USD (reported in $thousands on 13F). Source: SEC EDGAR.